Home
World Journal of Biology Pharmacy and Health Sciences
ISSN Approved | International, Peer reviewed, Referred, Open access Journal

Main navigation

  • Home
    • Journal Information
    • Abstracting and Indexing
    • Editorial Board Members
    • Reviewer Panel
    • Journal Policies
    • WJBPHS CrossMark Policy
    • Publication Ethics
    • Current Issue
    • Issue in Progress
    • Past Issues
    • Instructions for Authors
    • Article processing fee
    • Track Manuscript Status
    • Get Publication Certificate
    • Become a Reviewer panel member
    • Join as Editorial Board Member
  • Contact us
  • Downloads

ISSN Approved Journal | | IMPACT FACTOR 8.16 | | eISSN: 2582-5542 | |  Free Crossref DOI 

Fast Publication within 2 days after Acceptance | | Low Article Processing Charges | | Peer Reviewed and Referred Journal

Research and review articles are invited for publication in November 2026 (Volume 28, Issue 2) Submit Paper

Structure-Based Molecular Docking and ADME Profiling of Novel Thienopyrimidines as Dual VEGFR/EGFR Inhibitors in Colorectal Cancer

Breadcrumb

  • Home
  • Structure-Based Molecular Docking and ADME Profiling of Novel Thienopyrimidines as Dual VEGFR/EGFR Inhibitors in Colorectal Cancer

Priya A *, Shachindra L. Nargund, Mahesh Kumar N and Sharmila A. Gote

Department of Pharmaceutical Chemistry, Nargund College of Pharmacy, Bengaluru-560085, India.

Research Article

World Journal of Biology Pharmacy and Health Sciences, 2025, 23(01), 528–536

Article DOI: 10.30574/wjbphs.2025.23.1.0716

DOI url: https://doi.org/10.30574/wjbphs.2025.23.1.0716

Received on 14 June 2025; revised on 26 July 2025; accepted on 29 July 2025

Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths globally, contributing to nearly 10% of all cancer cases and 9.4% of cancer mortalities, as reported by recent GLOBOCAN data. Targeting receptor tyrosine kinases such as vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) has become a vital strategy in cancer therapeutics due to their key roles in tumor angiogenesis and cell proliferation. In this study, a series of novel thienopyrimidine derivatives were computationally evaluated for their potential as dual inhibitors of VEGFR and EGFR using a structure-based drug design approach. The crystal structures of VEGFR2 (PDB ID: 6GQP) and EGFR (PDB ID: 5D41) were retrieved from the Protein Data Bank and prepared using AutoDock Tools. Thienopyrimidine derivatives were designed using ChemDraw, energy-minimized, and converted into 3D structures. Molecular docking simulations were conducted using AutoDock Vina within PyRx, and protein-ligand interactions were analyzed using PyMOL and Discovery Studio. Docking results revealed that compounds PAS1 and PAS9 exhibited the highest binding affinities toward both EGFR (–8.7 kcal/mol) and VEGFR (–8.6 and –8.0 kcal/mol, respectively), outperforming the reference drug Lenvatinib (–8.3 and –7.9 kcal/mol). Pharmacokinetic properties assessed using SwissADME indicated that most compounds complied with Lipinski’s rule of five, and demonstrated favorable absorption, bioavailability, and blood-brain barrier permeability. Overall, this study suggests that thienopyrimidine scaffolds possess promising dual-inhibitory potential and favorable drug-like properties, supporting their development as targeted therapies for colorectal cancer.

Colorectal cancer; Dual inhibition; EGFR; Molecular docking; Thienopyrimidines; VEGFR

https://wjbphs.com/sites/default/files/fulltext_pdf/WJBPHS-2025-0716.pdf

Preview Article PDF

Priya A, Shachindra L. Nargund, Mahesh Kumar N and Sharmila A. Gote. Structure-Based Molecular Docking and ADME Profiling of Novel Thienopyrimidines as Dual VEGFR/EGFR Inhibitors in Colorectal Cancer. World Journal of Biology Pharmacy and Health Sciences, 2025, 23(01), 528-536. Article DOI: https://doi.org/10.30574/wjbphs.2025.23.1.0716.

Get Certificates

Get Publication Certificate

Download LoA

Check Corssref DOI details

Issue details

Issue Cover Page

Editorial Board

Table of content


Copyright © Author(s). All rights reserved. This article is published under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as appropriate credit is given to the original author(s) and source, a link to the license is provided, and any changes made are indicated.


Copyright © 2026 World Journal of Biology Pharmacy and Health Sciences (WJBPHS) - All rights reserved

Developed & Designed by VS Infosolution